ISU to begin canine anticancer immunotherapeutic agent clinical trialsFebruary 28, 2019Iowa State University (ISU) College of Veterinary Medicine is starting a clinical study for a new canine anticancer immunotherapeutic. Produced by NovaVive, the anticancer treatment, Immunocidin, has received regulatory approval in the U.S. and Canada to treat mammary tumors. The study will observe dogs with stage I or stage II splenic hemangiosarcoma (HSA) who have undergone a splenectomy to determine the effectiveness of Immunocidin in combination with doxorubicin chemotherapy. Sixty-six dogs will participate in the trial and survival times will be monitored. "Treatment options and survival outcomes for canine HSA have remained essentially stagnant for the past two decades," said Chad Johannes, DVM, DACVIM (SAIM, oncology). "Additional therapeutic options for HSA are needed and we look forward to learning more about how immune stimulation via Immunocidin may play a role in improving outcomes for dogs." Ten oncology clinics will participate in the trial. To find one, visit bit.ly/2D56wBv and enter AAHSD004874 in the keyword search.
SPONSORED CONTENTOne dose protects for 12 months.One ProHeart® 12 (moxidectin) injection puts compliance in your control. + Get started
VolitionRx tests nucleosome diagnostic for veterinary space applicationsOctober 5, 2018 VolitionRx Ltd., a multinational Belgium-based life sciences company with offices in Texas, London, and Singapore, announced it is entering the veterinary market after "very encouraging" preliminary results from a study using its NuQ diagnostic blood tests for canine cancer testing. NuQ, currently used to screen for colorectal and prostate cancers, works by measuring and analyzing irregular levels of nucleosomes—a section of DNA wrapped around a core of proteins—in the blood to identify cancers. According to the company, the proof-of-concept study showed that blood nucleosomes also can be detected in dogs. With the promise of veterinary medicine applications, VolitionRx said it will now move NuQ into larger trials to answer the question of whether the method will work with animals. The company said it intends to outsource much of the veterinary clinical trial work through a partnership with Heather Wilson-Robles, DVM, DACVIM, associate professor and Fred and Vola N. Palmer chair in comparative oncology with Texas A&M College of Veterinary Medicine & Biomedical Sciences in the Small Animal Clinical Sciences department. "The Texas A&M University College of Veterinary Medicine Oncology Department is excited for the opportunity to collaborate with Volition," said Dr. Wilson-Robles. "Its innovative work in …
UC Davis study applies human cancer differentiation analysis to dogsOctober 4, 2018The University of California, Davis, School of Veterinary Medicine (UCDSVM) is conducting a clinical trial to study the potential application for canine cancer screening using cancer differentiation analysis (CDA) liquid biopsy technology from Anpac Bio-Medical Science Co. Studying at least 186 dogs in a blinded clinical trial, Anpac Bio and UCDSVM are investigating CDA's ability to identify cancer in blood samples from dogs confirmed with sarcomas or carcinomas versus healthy control blood samples from dogs of similar age and breed. Following the initial screening, UCDVSM will then test if CDA levels also correlate to treatment response (i.e. if the dogs' cells are responding to cancer treatment such as surgery or radiation) and monitor remission/potential recurrence. "Dogs are just like people; the sooner we identify disease, the better chance we have in treating and curing it," said John Reddington, DVM, PhD, Anpac Bio's chief advisor for veterinary and comparative research. "Unfortunately, dogs can't tell us when they don't feel well, so, we often catch diseases like cancer late stage. [Anpac Bio's] cancer differentiation analysis liquid biopsy technology has proven to be very useful in detecting over 20 human cancer types with just a single …
Veterinary study shows promise for noninvasive echotherapy treatmentJune 5, 2018 A canine cancer patient was found to be cancer free following a noninvasive focused ultrasound treatment, reports Theraclion, a company specializing in medical equipment for echotherapy. The procedure was administered as part of a veterinary study at the Virginia-Maryland College of Veterinary Medicine (VMCVM), financed by the Focused Ultrasound Foundation, which is investigating the treatment of dogs with sarcomas and mast cell tumors with Theraclion's Echopulse technology. "These canine tumors tend to occur on the limbs and may recur if they are not entirely removed. As a result, often amputation is required," said Jeffrey Ruth, DVM, DAVBP, DACVR, clinical assistant professor of radiology at VWCVM. "It is our hope that focused ultrasound will add to current treatment options by providing a way to noninvasively ablate the mass and also trigger an anti-tumor immune response." The study is one of several launched by the Focused Ultrasound Foundation in its veterinary program to develop focused ultrasound therapies for the treatment of companion animals. While the technology was originally designed to treat tumors in humans, its robotic design allowed for it to be easily adapted for veterinary uses, according to Theraclion. "As veterinary treatments are …
Tufts veterinarians treat canine cancer with experimental drugJanuary 18, 2018When Edward Sloan's dog, Dozer, a 7-year-old bull mastiff went blind seemingly overnight, a devastating diagnosis revealed Dozer had cancer. Desperate to save his best friend, Sloan found a clinical trial at the Cummings School of Veterinary Medicine at Tufts University, where Abbey Sadowski, DVM, found that Dozer had "lost a lot of weight [and] had several weeks of history before he even saw us." Dr. Sadowski and Cheryl London, DVM, Ph.D., are testing an experimental drug—called KPT-9274—combined with just one round of chemotherapy to treat lymphoma. "We had this remarkable response … when you combine these two things together you can get a dramatic reduction in disease," Dr. London said. Early results of the small study have been promising, especially for Sloan and Dozer. "A single heroic dose … the next day he was able to see," Sloan said. Dozer is three months in remission, and his medical reversal of fortune could eventually lead to a breakthrough in human medicine. London said the outcome of a canine trial is a valuable piece of the research puzzle. "The benefits to the human side are that you get a drug into humans that's actually much …
ASU awarded $6.4M grant to test preventive canine cancer vaccineJanuary 8, 2018Arizona State University (ASU) professor Stephen Albert Johnson, Ph.D., has received a $6.4 million grant from the Open Philanthropy Project to support a clinical trial of a vaccine to prevent canine cancer. The trial will involve approximately 800 middle-aged, healthy pet dogs and will test the effects of a multivalent frameshift peptide (FSP) vaccine developed at ASU that has shown promise in mouse studies. Scientists think the vaccine has potential for human use, too. "Our goal has always been that if this is possible, we should at least try it," said Johnston, director of the Biodesign Center for Innovations in Medicine and CEO of Calviri Inc., a cancer vaccine company. "Open Philanthropy was the only organization that responded to support our high-risk project, the biggest cancer intervention trial in dogs ever." Johnston and his team developed the new FSP vaccine over the past 10 years. The vaccine, already tested for efficacy in mice, is shown to be safe in dogs, according to Johnston's research. Cancer is the leading cause of death in pet dogs and their cancers are very similar to their human counterparts. Some breeds have a very high cancer rate, as much as 40 percent. The canine …
Animal Cancer Foundation receives $1 million for canine cancer genome projectNovember 8, 2017 The Animal Cancer Foundation (ACF), a national nonprofit organization that supports comparative oncology research that studies the similarities between cancers in people and pets to help find cures for both, has received a $1 million dollar donation from the Blue Buffalo Foundation. The grant will provide funding for the Canine Cancer Genome Project (CCGP), which will map the tumor genomes of the most common canine cancers. Understanding the genetic makeup of canine cancer tumors, and comparing their genetic makeup to those of people with cancer, will allow researchers to discover additional targeted drug therapies and the least toxic doses of those therapies that are most effective in curing the individual, whether canine or human, according to ACF. The initiative arose as a result of a review conducted in 2015 by the Institute of Medicine of the National Academy of Science and supported in part by ACF that highlighted the value of comparative oncology and the inclusion of veterinary oncologists in accelerating cancer drug development. ACF has pledged to raise an additional $1 million dollars in support of the CCGP. The fundraising effort is supported by Blue Buffalo Foundation, which has partnered with …
Michigan specialty veterinary care center seeks dogs for cancer studySeptember 19, 2017 Oakland Veterinary Referral Services (OVRS) specialty veterinary care center is conducting a nationwide study on dogs with canine splenic hemangiosarcoma (HSA) and the benefits of using traditional Chinese herbal medicine (TCHM) as treatment to significantly extend life expectancy. Erin Bannink, DVM, DACVIM, VCHM, CVA, is leading the study, according to Lucy Henney, DVM, DACVS, owner of Bloomfield Hills, Mich.-based OVRS. Most dogs diagnosed with HSA are treated by removal of the spleen after the tumor has ruptured and bled, causing life-threatening blood loss; most dogs living only two months after surgery due to the spread of cancer to other organs, according to Dr. Bannink. Because of HSA's aggressive nature, chemotherapy is usually recommended after surgery in the hope of prolonging life, but it only modestly prolongs survival, and most dogs still die of cancer spread within three to four months of diagnosis, she said. "The purpose of this study is to determine if treatment with a specific herbal therapy regimen is helpful in prolonging survival time after surgery in dogs with HSA and no evidence of cancer spread," said Bannink. "We hypothesize that dogs treated with this standardized protocol after splenectomy will have …
NIH issues grant to further canine cancer researchSeptember 30, 2016The National Institutes of Health (NIH) recently awarded a $500,000 grant to fund a study aimed at increasing the understanding about the interactions between cancer and the immune system in dogs with naturally occurring tumors. The researchers will then apply that knowledge to the understanding of human cancer.
How studying cancer in dogs will help humansJuly 11, 2016Using rodent models to study cancer in people hasn’t benefited people much. In recent years, computer studies have furthered knowledge about cancer treatments, but you can’t conduct clinical drug trials on computers.
